STOCKS TELEGRAPH

Tag: NASDAQ:LEXX

  • Lexaria Bioscience (LEXX) Experiences Continued Stock Surge

    Lexaria Bioscience (LEXX) Experiences Continued Stock Surge

    Last Friday, Lexaria Bioscience Corp. (NASDAQ: LEXX) had outstanding stock performance for the third day in a row, helped by encouraging findings from a recent pilot clinical research. The company’s stock increased by 21.05% to close at $3.91 after rising by more than 10% the day before.

    Lexaria Shared Clinical Research Success

    The results of Lexaria Bioscience’s human pilot study #2, GLP-1-H24-2, which examined the pharmacokinetics and tolerability of their Rybelsus capsules processed using DehydraTECH, were made public. Designed to administer the GLP-1 medication semaglutide, these capsules showed better tolerability than the Rybelsus tablets that are sold commercially.

    Notably, none of the nine participants who consumed the DehydraTECH-processed Rybelsus capsules experienced adverse events. In contrast, six of the nine participants who took the standard Rybelsus tablets reported mild adverse effects.

    Comparative Analysis of Tolerability

    The study also included an evaluation of the DehydraTECH-processed Rybelsus in a dissolvable oral format. Five of the six individuals who experienced mild adverse events from the Rybelsus tablets also reported similar issues with the dissolvable format.

    These findings are consistent with those from Lexaria’s prior human pilot study #1, GLP-1-H24-1, which had also shown that DehydraTECH-processed Rybelsus capsules were generally better tolerated than Rybelsus tablets, which had induced moderate nausea or diarrhea.

    LEXX Planning Future Implications And Ongoing Research

    The results suggest a potential for decreased adverse events with DehydraTECH-processed Rybelsus capsules compared to the commercially available tablets. This is particularly notable given that Rybelsus is known to produce higher incidences of side effects compared to the injectable product Ozempic, which outsells it significantly.

    If further clinical testing confirms these findings, DehydraTECH’s enhanced oral tolerability could potentially drive greater adoption of oral GLP-1 therapies. Additionally, the study’s third arm, which assessed the DehydraTECH-processed Rybelsus as a dissolvable in-mouth tablet, showed promising results from a conceptual standpoint.

    Analysis of blood samples from the 20-minute to 24-hour marks revealed that the DehydraTECH-processed Rybelsus mouth-melt had a 32.3% and 106.9% higher systemic absorption rate compared to the standard Rybelsus tablet, respectively.

  • Lexaria Bioscience (LEXX): After-Hours Stock Growth Fueled by Recent Study Results

    Lexaria Bioscience (LEXX): After-Hours Stock Growth Fueled by Recent Study Results

    Lexaria Bioscience Corp. (NASDAQ: LEXX) experienced a significant rise in its stock value during the after-market session on Monday, following a period of stability during regular trading hours. The company’s shares increased by 6.60%, reaching $3.39 after hours on the US stock charts. This surge was driven by the release of promising study results by the company, highlighting advancements in their ongoing research initiatives.

    Lexaria Formed Promising Research Collaboration with NRC

    Lexaria (LEXX) recently published positive findings from a collaborative study initiative with the National study Council of Canada (NRC). In conjunction with semaglutide, a drug that functions as a glucagon-like peptide-1, or GLP-1, the study’s objective was to evaluate significant aspects of DehydraTECH’s mode of action.

    Semaglutide is an active ingredient in Rybelsus, a prescription drug used to treat Type 2 diabetes, therefore this finding is very significant. Using artificial gastric juice to replicate the conditions of the human gut, the study included a detailed examination of the molecular properties of Rybelsus and semaglutide that had been processed by DehydraTECH.

    Advanced testing methods, including polyacrylamide gel electrophoresis (PAGE), size exclusion chromatography (SEC), electrospray ionization mass spectrometry (ESI-LCMS), and dynamic light scattering (DLS), were employed to assess the performance of the formulations.

    LEXX Shared Encouraging Results and Future Prospects

    The findings from the PAGE and SEC analyses were particularly noteworthy, revealing that semaglutide was efficiently released in its monomeric form in the simulated gastric fluid across both formulations. This outcome is significant because the monomeric form of semaglutide is crucial for its ability to permeate the gastric epithelium and be delivered systemically.

    Notably, Lexaria’s DehydraTECH technology achieved this result without the proprietary salcaprozate sodium (SNAC) ingredient, which is integral to Rybelsus. While the results from the DLS and ESI-LCMS testing were less conclusive, the overall findings support the potential of DehydraTECH in GLP-1 formulation and oral delivery.

    Lexaria, in collaboration with the NRC, plans to conduct further experimentation to expand on this work, potentially under additional conditions that more closely mimic the human gut environment.

  • How Lexaria (LEXX) Stock Is Maintaining A Higher Trajectory?

    How Lexaria (LEXX) Stock Is Maintaining A Higher Trajectory?

    The current market activity surrounding Lexaria Bioscience Corp. (NASDAQ: LEXX) underscores a notable upsurge in its stock performance on the US market today. At the latest check during the current trading session, Lexaria’s stock exhibited a marked increase of 22.63%, reaching a trading value of $2.33. Although this surge in LEXX stock occurred in the absence of immediate news, recent developments shed light on the factors influencing its market behavior.

    Notably, on January 29, Lexaria (LEXX) disclosed that company has finally submitted an Investigational New Drug (“IND”) application to the Food and Drug Administration (“FDA”). This application relates to its planned phase 1b clinical research, HYPER-H23-1, in the United States, which uses DehydraTECH-CBD to treat hypertension.

    This IND submission followed a productive pre-IND meeting with the FDA, during which Lexaria received valuable guidance regarding the development and filing processes associated with the IND. Noteworthy is the fact that from 2018 through 2023, Lexaria sponsored five investigator-initiated human clinical studies evaluating DehydraTECH-CBD, encompassing a total of 134 participants.

    Importantly, these studies yielded promising results, showcasing significant reductions in resting blood pressure across various dosing regimens, both independently and, in certain instances, in conjunction with standard of care medications. Such findings underscore the potential broad therapeutic applications of DehydraTECH-CBD.

    Per the FDA’s protocol, once an IND is submitted, a mandatory 30-day waiting period ensues before any clinical trials can commence. This interval allows the FDA to meticulously review the submitted IND to ensure the safety of research subjects and mitigate any potential risks.

    Lexaria is currently directing its efforts towards the expeditious initiation of clinical trial HYPER-H23-1 post-IND approval, contingent upon various factors, including securing adequate funding. The successful conclusion of the IND review process will represent a significant milestone for Lexaria, affirming the rigorous regulatory scrutiny applied to its DehydraTECH technology in the context of prospective pharmaceutical commercial registration.